Pharmacoeconomics Evaluation of CYP2C19 Genetic Test Guiding Antiplatelet Therapy for Acute Coro-nary Syndrome Patients in China
10.6039/j.issn.1001-0408.2017.23.04
- VernacularTitle:CYP2C19基因检测指导我国急性冠脉综合征患者抗血小板治疗方案的药物经济学评价
- Author:
Ailin CAO
;
Jiao QIAN
;
Zhuo WANG
- Keywords:
Ticagrelor;
Clopidogrel;
Genetic test;
Pharmacoeconomics;
Cost-effectiveness analysis;
CYP2C19 gene
- From:
China Pharmacy
2017;28(23):3183-3187
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To evaluate the feasibility of using CYP2C19 gene to guide the use of antiplatelet agents in acute cor-onary syndrome(ACS)patients undergoing interventional operation in China from the viewpoint of pharmacoeconomics. METH-ODS:Based on global PLATO trial data,the patients were divided into 3 groups according to treatment strategies(clopidogrel group,ticagrelor group,genetic test group). By applying Treeage Pro 2011 software,short-term decision tree model and long-term Markov model were established,and related data were imported to evaluate cost-effectiveness of different treatment strategies. RE-SULTS&CONCLUSIONS:For ACS patients,according to the level of GDP in China,conventional use of ticagrelor is of pharma-coeconomic advantage for in Shanghai and uninsured patients insured patients;the use of antiplatelet agents guided by CYP2C19 gene test is of pharmacoeconomic advantage among nationwide insured patients.
